

## AUTHOR INDEX

- Ambalavanan, N., 192  
Anderson, P.J., 227  
Aranda, J.V., 114
- Bancalari, E., 164  
Bard, H., 113  
Barfield, W., 54, 61  
Baveja, R., 209  
Benders, M.J., 146  
Bettgowda, V.R., 8  
Bhandari, A., 219  
Bhandari, V., 163, 185  
Bhutani, V.K., 89  
Biniwale, M.A., 200  
Bry, K., 121  
Bullard, J.E., 327
- Carlo, W.A., 192  
Checchin, D., 129  
Chemtob, S., 129  
Chess, P.R., 171  
Chessex, P., 139  
Christou, H., 209  
Clapp, D.W., 69  
Clark, R.H., 28  
Clark, S.M., 276  
Claure, N., 164  
Cleary-Goldman, J., 103  
Coalson, J.J., 179
- D'Alton, M.E., 103  
Damus, K., 8  
D'Angio, C.T., 171  
Davidoff, M.J., 8  
Declercq, E., 61, 235  
De Vries, L.S., 146  
Dias, T., 8  
Dolan, S., 8  
Doyle, L.W., 227  
Druzin, M.L., 305  
Dudell, G.G., 296
- Eaton, D.C., 34  
Ehrenkranz, R.A., 200  
El-Sayed, Y.Y., 305  
Engle, W.A., 2
- Escobar, G.J., 28, 44  
Evans, S., 54, 61
- Fanaroff, A.A., 151  
Fanaroff, J.M., 151  
Fenner, D., 261  
Ferkol, T., 335
- Gilliam, M., 257  
Glasser, S.W., 341  
Gow, A., 139  
Green, N.S., 8  
Greene, J.D., 28  
Groenendaal, F., 146  
Gruen, J.R., 185
- Haataja, R., 350  
Hallman, M., 350  
Hamvas, A., 315, 316  
Handa, V.L., 253  
Hankins, G.D.V., 20, 276  
Harrison, A., 139  
Hauth, J.C., 98  
Haxhiu, M.A., 156  
Hemachandra, A., 288  
Hunt, C.E., 73
- Jackson, G.L., 24  
Jain, L., 34, 296  
Johnson, L., 89
- Kermorvant-Duchemin, E., 129  
Khashu, M., 139  
Kinney, H.C., 81  
Klebanoff, M., 288  
Kooli, A., 129  
Kotelchuck, M., 54, 61
- Lachapelle, P., 129  
Lalari, V., 139  
Lappalainen, U., 121  
Laptook, A., 24  
Lavoie, J.-C., 139  
Leduc, M., 129  
Lee, Y.M., 103  
Leigh, M., 335  
Longo, M., 20
- Macdorman, M.F., 235  
Maniscalco, W.M., 171  
Martin, R.J., 156  
McCormick, M.C., 44  
Menacker, F., 235  
Minkoff, H., 309  
Munn, M.B., 276
- Naninni, A., 61  
Neu, J., 77  
Nogee, L.M., 315, 327, 341  
Nygaard, I., 267
- Oh, W., 113
- Panitch, H.B., 219  
Petrini, J., 8  
Pryhuber, G.S., 171
- Raju, T.N.K., 1, 53  
Reddy, U.M., 233  
Richardson, D.K., 44  
Richter, H.E., 272  
Russell, R., 8
- Sachs, B., 242  
Schwarz, R.H., 8  
Sennlaub, F., 129  
Shapiro-Mendoza, C.K., 54, 61  
Sibai, B.M., 16  
Signore, C., 288  
Sirinyan, M., 129  
Spong, C.Y., 233
- Thomas, R., 114  
Tomashek, K.M., 54, 61
- Vadnais, M., 242
- Ward, R.M., 48  
Wax, J.R., 247  
Weiss, J., 54, 61  
Wert, S.E., 327
- Yao, Q., 156
- Zaidi, S.I., 156  
Zheng, Z., 44

## SUBJECT INDEX

- ABCA3 deficiency, 315, 327-328  
clinical findings, 329-330  
pathology, 328-329  
and pediatric interstitial lung disease, 330-332  
treatment, 333
- ABCA3 deficiency, 315, 327-328 (*Continued*)  
Academic performance, in BPD, 229-230  
N-Acetyl-cysteine, for BPD, 214  
Adaptive immune system, developmental regulation of, 70-71  
Airway disease, in BPD, 223



- Allopurinol, for BPD, 214-215
- Alpha-1 proteinase inhibitor, for BPD, 215
- Alveolization, and BPD pathology, 179-183
- Anal incontinence
- cesarean delivery and, 263-265
  - effect of subsequent vaginal delivery, 262-263
  - after sphincter disruption, 261-262
- Angiotensin converting enzyme, and BPD pathogenesis, 188
- Animal models, vs. human, BPD pathology in, 181-183
- Antioxidants, for BPD
- N-acetyl-cysteine, 214
  - allopurinol, 214-215
  - nitric oxide, 215
  - superoxide dismutase, 214
  - vitamin C, 214
  - vitamin E, 214
- Antiproteinases, for BPD, 215
- Apnea of prematurity, in infants born 34-37 weeks postmenstrual age, ontogeny of, 74
- Apparent life-threatening events, in late preterm infants born 34-37 weeks postmenstrual age, ontogeny of, 74
- Trans-arachidonic acids, and microvascular degeneration, in pathogenesis of retinopathy of prematurity, 134-136
- Ascorbic acid. *See* Vitamin C
- Attention, in BPD, 228-229
- Autonomic regulation, in late preterm infants born 34-37 weeks postmenstrual age, ontogeny of, 73-76
- apnea of prematurity, 74
  - apparent life-threatening events, 74
  - Collaborative Home Infant Monitoring Evaluation, 74-75
  - maturation of sleep stage regulation, 74
  - sudden infant death syndrome, 75
- Bilirubin, interaction with ibuprofen in preterm newborns, 118
- Biochemical analysis, of inherited disorders of surfactant metabolism, 321
- Birth weight
- and gestational age classification system, 2-5
  - low, impact of multiple gestations, 105
- BPD. *See* Bronchopulmonary dysplasia
- Brain, of late preterm infants, 81-87
- development and injury of, 81-83
  - maturational factors of the cerebral white matter, 85-86
  - and periventricular leukomalacia, 83-84
  - incidence, 84
  - pathogenesis, 84
- Brain-derived neurotrophic factor, role in neonatal lung and airway injury, 156-161
- Bronchodilators, for BPD, 212
- Bronchopulmonary dysplasia (BPD), 163
- definitions and diagnostic criteria, 165-166
  - classic vs. new, 164-165
  - physiologic definition, 169-170
  - population definition and competing outcomes, 167-168
  - predictive value, 169
  - supplemental oxygen at 28 days vs. 36 weeks postmenstrual age, 166-167
- neurodevelopmental outcomes in
- cognitive functioning, 228
  - neurosensory problems, 227-228
  - pathways to neuropsychological impairment, 230
  - psychological problems, 230
- pathogenesis of
- fluid management, 175-176
  - genetics, 176, 185-190
  - hyperoxia/hypoxia, 171-172
  - inflammation, 174-175
  - interleukin-1 $\beta$  and pulmonary retinoic acid pathways, 113, 121-126
  - mechanical forces, 172-173
  - mechanical ventilation, 172-173
  - nutrition, 176
- Bronchopulmonary dysplasia (BPD), 163 (*Continued*)
- patent ductus arteriosus, 175-176
  - surfactant, 172-173
  - vascular maldevelopment, 173-174
- pathology of, 179-181
- animal models vs. human, 181-183
- prevention and management of
- mechanical ventilation in, 192-199
  - nutrition in, 200-207
  - pharmacologic strategies, 209-216
- pulmonary outcomes in
- airway disease, 223
  - exercise testing, 223-224
  - pathology, 219-220
  - pulmonary function, 222-223
  - radiological findings, 224
  - respiratory morbidity, 220-222
- and surfactant protein polymorphisms, 358, 360
- Calcium, for VLBW infants with BPD, 204
- Cesarean section
- anal incontinence and, 263-265
  - background, trends and epidemiology, 235-241
  - elective, vs. expectant management, decision tree analysis of neonatal mortality and morbidity after, 288-294
  - elective repeat. *See* Elective repeat cesarean section
  - maternal mortality in, 242-246
  - on maternal request
    - ethics of, 309-312
    - impact on neonatal morbidity and mortality, 276-286
    - long term effects on reproductive health, 257-260
    - resource allocation of, 305-308
    - vs. planned vaginal delivery, impact on development of pelvic organ prolapse, 272-274
- on maternal request, vs. planned spontaneous vaginal delivery, maternal morbidity and short-term outcomes, 247-251
- in near-term pregnancies, 38-39
- respiratory morbidity after, 296-302
- clearance of fetal lung fluid, 299-300
  - rescue strategies in, 301
  - role of retained fetal lung fluid, 298-299
- risks and benefits of, 233-234
- urinary incontinence and, 267-270
- cross-sectional studies, 269
  - randomized trial, 270
  - risk of future surgery, 269-270
  - sister studies, 270
- Childbirth, and maternal sexual function, 253-256
- Chorioamnionitis, in spontaneous preterm labor and premature rupture of membranes at late preterm gestations, 99-102
- Cilia
- role in pulmonary defense, 336
  - structure and function, 335-336
- Cognitive function, in BPD, 228
- academic performance, 229-230
  - attention, 228-229
  - executive function, 229
  - language, 229
  - memory and learning, 229
  - visual-spatial perception, 229
- Cold stress, and hypoglycemia, in the late preterm infant, 24-27
- Collaborative Home Infant Monitoring Evaluation, in late preterm infants born 34-37 weeks postmenstrual age, 74-75
- Continuous positive airway pressure, for BPD, 196
- Continuous tracheal gas insufflation, for BPD, 195
- Cortisone, interaction with ibuprofen in preterm newborns, 118
- Costs, of cesarean delivery on maternal request, 305-308
- Cysteine, for BPD, 206

- Decision tree analysis, of neonatal morbidity and mortality after elective cesarean delivery vs. expectant management, 288-294
- Dexamethasone, for BPD, effects on growth, 201-202
- Dichorionic twin gestations, uncomplicated, elective late preterm delivery for, 109-110
- Diuretics, for BPD  
  loop diuretics, 211  
  thiazides, 211-212
- Drug disposition, in late preterm infants, 48-50
- ELBW infants. *See* Extremely low birth weight (ELBW) infants
- Elective repeat cesarean section (ERCS), neonatal morbidity in near-term infants born by  
  reduced by antepartum glucocorticoids, 38  
  severe hypoxic respiratory failure, 40  
  without trial of labor, 39-40
- Encephalopathy, neonatal, impact of cesarean delivery on maternal request, 283-285
- Enteral intake, for VLBW infants with BPD, 203-204
- Enteral nutrition, minimal, in preterm infants, enhanced by photoprotection of parenteral nutrition, 113, 139-144
- Epidemiology  
  of cesarean section, 235-241  
  of inherited surfactant protein-B deficiency, 318  
  of surfactant protein-C associated disease, 320-321
- ERCS. *See* Elective repeat cesarean section
- Erythromycin, for BPD, 215
- Ethics, of cesarean section on maternal request, 309-312
- Executive function, in BPD, 229
- Exercise testing, in BPD, 223-224
- Extremely low birth weight (ELBW) infants, short- and long-term consequences of hypotension in, 113, 151-154
- Feeding, and gastrointestinal maturation, 77-80
- Feeding difficulties, BPD-associated, 201
- Fetal lung fluid, clearance, physiology of, 34-40  
  active sodium transport and, 35-36  
  cesarean sections in near-term pregnancies, 38-39  
  delayed transition in near-term infants, 35  
  developmental changes in ion conductances, 36-37  
  enhanced by postnatal approaches, 37-38  
  glucocorticoids, 37-38  
  respiratory morbidity, 39-40  
  role of alveolar environment, 37
- Fetal trauma, impact of cesarean delivery on maternal request, 281-283
- Fluid management, and BPD pathogenesis, 175-176
- Fluid restriction, for VLBW infants with BPD, 202-203
- Gastrointestinal adverse effects, of intravenous ibuprofen in preterm newborns, 118
- Gastrointestinal maturation, and feeding, 77-80
- Genetically engineered mice, 315  
  examples related to surfactant metabolism and neonatal lung disease  
    surfactant protein-A and D knock-outs, 346-347  
    surfactant protein-B knock-out, 344-345  
    surfactant protein-C and other promoters, 343-344, 345-346  
  types of, 341-343
- Genetic analysis, of inherited disorders of surfactant metabolism, 322-323
- Genetic polymorphism, surfactant, 355-356  
  and neonatal lung disease, 315  
    and respiratory syncytial virus infection, 357-359  
    and risk of BPD, 357, 359  
    and risk of respiratory distress syndrome, 356-358  
  as risk factor of multifactor disease, 350-351  
  surfactant proteins as candidate genes, 351-355
- Genetics  
  and BPD pathogenesis, 176, 185-186  
    heritability studies, 187  
    multiple births and, 187
- Genetics (*Continued*)  
  potential candidate genes, 187-190  
  of primary ciliary dyskinesia, 337-338
- Gestational age  
  and birth weight classification system, 2-5  
  distribution among U.S. singleton births, impact on rates of late preterm birth, 8-15
- Gestational hypertension. *See* Preeclampsia
- Glucocorticoids, for enhanced lung fluid reabsorption, 37  
  antepartum administration of, 38
- Glutamine, for BPD, 205-206
- Glutathione S transferase, and BPD pathogenesis, 188
- Growth, effects of dexamethasone for BPD on growth, 201-202
- Growth failure, and BPD, 200-201
- Hematologic adverse effects, of intravenous ibuprofen in preterm newborns, 118
- High frequency ventilation, for BPD, 195
- Hospital discharge, early, relation to risk of neonatal morbidity among late preterm and term newborns, 61-67
- Hypercapnia  
  nitrate stress induced by, in pathogenesis of retinopathy of prematurity, 131-134  
  permissive, as target of ventilation for BPD, 192-193
- Hyperoxia  
  and BPD pathogenesis, 171-172  
  and neonatal lung injury, 157-158
- Hypoglycemia, and cold stress, in the late preterm infant, 24-27
- Hypotension, short- and long-term consequences in ELBW infants, 113, 151-154
- Hypoxemia, permissive, as target of ventilation for BPD, 193-194
- Hypoxia, and BPD pathogenesis, 171-172
- Hypoxia-ischemia, perinatal, MRI of pre-Wallerian degeneration in neonate after, 113, 146-150
- Ibuprofen, intravenous, for patent ductus arteriosus closure in preterm newborns, 113, 114-119  
  adverse effects and potential drug-drug interactions, 118  
  aminoglycosides interaction and renal effects, 118  
  clinical studies  
    with lysine or THAM, 115  
    vs. indomethacin, 115-116  
  pharmacodynamics  
    dose finding, 117  
    efficacy in intraventricular hemorrhage, 117  
    meta-analyses, 116-117  
    oral ibuprofen, 116  
  pharmacokinetics, metabolism and disposition, 117-118
- Immune system, developmental regulation of, 69-72  
  functions of innate and adaptive systems, 70-71  
  toll-like receptors, 71-72
- Indomethacin, vs. ibuprofen, for patent ductus arteriosus closure in preterm newborns, 115-116
- Infants, and women, care in late preterm gestations, 1, 53
- Inflammation, and BPD pathogenesis, 174-175
- Innate immune system, developmental regulation of, 70-71
- Inositol, for BPD, 205, 214
- Insulin-like growth factor-I, and BPD pathogenesis, 188-189
- Insulin-like growth factor-I receptor, and BPD pathogenesis, 188-189
- Intensive care unit, neonatal  
  relation of cold stress and hypoglycemia to admission of preterm infants in, 24-27  
  relation of late preterm delivery to admissions to, 18
- Interleukin-1 $\beta$ , and pulmonary retinoic acid pathways in BPD pathogenesis, 113, 121-126
- Interleukin-4, and BPD pathogenesis, 189
- Interleukin-10, and BPD pathogenesis, 189
- Interstitial lung disease, pediatric, and ABCA3 deficiency, 330-332
- Intrauterine fetal demise. *See* Stillbirths

- Intrauterine growth restriction, as indication for late preterm delivery, 108-109
- Intraventricular hemorrhage, in preterm newborns, efficacy of ibuprofen, 117
- Iron, for BPD, 205
- Kernicterus, in late preterm infants, 89-97
- Language, in BPD, 229
- Learning, and memory, in BPD, 229
- Liquid ventilation, for BPD, 196
- Loop diuretics, for BPD, 211
- Low birth weight, impact of multiple gestations, 105
- Low birth weight infants, extremely, short- and long-term consequences of hypotension in, 113, 151-154
- Lung and airway injury, neonatal, role of neurotrophins in, 113, 156-161
- hyperoxia and, 157-158
- Lung biopsy, in evaluation of inherited disorders of surfactant metabolism, 323
- Lung disease  
neonatal, genetically engineered mice related to  
surfactant protein-A and D knock-outs, 346-347  
surfactant protein-B knock-out, 344-345  
surfactant protein-C and other promoters, 343-344, 345-346  
pediatric interstitial, and ABCA3 deficiency, 330-332
- Lung fluid, fetal  
clearance, physiology of, 34-40  
active sodium transport and, 35-36  
cesarean sections in near-term pregnancies, 38-39  
delayed transition in near-term infants, 35  
developmental changes in ion conductances, 36-37  
enhanced by postnatal approaches, 37-38  
glucocorticoids, 37-38  
respiratory morbidity, 39-40  
role of alveolar environment, 37  
in respiratory morbidity after cesarean section  
clearance of, 299-300  
retained fluid, 298-299
- Lung pathology, in BPD, 179-183, 219-220
- Lysine-ibuprofen, for patent ductus arteriosus closure in preterm newborns, 115
- Magnetic resonance imaging (MRI), of pre-Wallerian degeneration in neonate after perinatal hypoxia-ischemia, 113, 146-150
- Mast cell stabilizer, for BPD, 213-214
- Maternal morbidity, in planned spontaneous vaginal delivery vs. cesarean section on maternal request, 247-251
- Maternal mortality, in cesarean section, 242-246
- Maternal sexual function, and childbirth, 253-256
- Mechanical ventilation, and BPD  
pathogenesis, 172-173  
prevention and management, 192-199  
ancillary strategies, 196-197  
continuous positive airway pressure, 196  
continuous tracheal gas insufflation, 195  
established BPD, 197  
high frequency ventilation, 195  
liquid ventilation, 196  
lower pressures, faster rates, shorter inspiratory times, 194-195  
patient-triggered ventilation, 195  
targeting permissive hypercapnia, 192-193  
targeting permissive hypoxemia, 193-194  
volume-targeted ventilation, 195
- Memory, and learning, in BPD, 229
- Methionine, for BPD, 206
- Mice, genetically engineered, 315  
examples related to surfactant metabolism and neonatal lung disease  
surfactant protein-A and D knock-outs, 346-347  
surfactant protein-B knock-out, 344-345
- Mice, genetically engineered, 315 (*Continued*)  
surfactant protein-C and other promoters, 343-344, 345-346  
types of, 341-343
- Microvascular degeneration, and trans-arachidonic acids, in pathogenesis of retinopathy of prematurity, 134-136
- Minimal enteral nutrition, in preterm infants, enhanced by photoprotection of parenteral nutrition, 113, 139-144
- Monoamnioticity, as indication for late preterm delivery, 109
- Monochorionicity, as indication for late preterm delivery, 109
- Monochorionic twin gestations, uncomplicated, elective late preterm delivery for, 110
- Monocyte chemoattractant protein-1, and BPD pathogenesis, 189
- Morbidity  
maternal, in planned spontaneous vaginal delivery vs. cesarean section on maternal request, 247-251  
neonatal. *See* Neonatal morbidity  
respiratory. *See* Respiratory morbidity
- Mortality  
maternal, in cesarean section, 242-246  
neonatal. *See* Neonatal mortality
- MRI. *See* Magnetic resonance imaging
- Multiple births, and BPD pathogenesis, 187
- Multiple gestations, 103-112  
impact on perinatal outcomes  
adverse neurodevelopmental outcomes, 105-106  
low birth weight, 105  
and mode of conception, 106  
perinatal mortality and morbidity, 104-105  
late preterm deliveries for  
elective deliveries, 109-110  
potential indications, 107-109  
prevention of, 106-107
- Near-term infants. *See* Preterm infants, late
- Near-term labor and birth. *See* Preterm labor and birth, late
- Neonatal encephalopathy, impact of cesarean delivery on maternal request, 283-285
- Neonatal intensive care unit  
relation of cold stress and hypoglycemia to admission of preterm infants in, 24-27  
relation of late preterm delivery to admissions to, 18
- Neonatal lung disease  
genetically engineered mice related to  
surfactant protein-A and D knock-outs, 346-347  
surfactant protein-B knock-out, 344-345  
surfactant protein-C and other promoters, 343-344, 345-346  
and surfactant protein polymorphisms, 315, 350-356  
BPD, 357, 359  
respiratory distress syndrome, 356-358  
respiratory syncytial virus infection, 357-359
- Neonatal morbidity  
among "healthy," late preterm newborns, risk factors for, 54-60  
after elective cesarean delivery vs. expectant management, decision tree analysis of, 288-294  
impact of cesarean delivery on maternal request, 276-286  
impact of multiple gestations, 104-105  
in near-term infants born by ERCS  
reduced by antepartum glucocorticoids, 38  
severe hypoxic respiratory failure, 40  
without trial of labor, 39-40  
risk among late preterm and term newborns, relation to early discharge, 61-67
- Neonatal mortality  
among "healthy," late preterm newborns, risk factors for, 54-60  
after elective cesarean delivery vs. expectant management, decision tree analysis of, 288-294  
impact of cesarean delivery on maternal request, 276-286  
impact of multiple gestations, 104-105
- Nerve growth factor, role in neonatal lung and airway injury, 156-161

- Neurodevelopmental outcomes
  - in BPD
    - cognitive functioning, 228
    - neurosensory problems, 227-228
    - pathways to neuropsychological impairment, 230
    - psychological problems, 230
  - of hypotension in ELBW infants, 113, 151-154
- Neurologic injury, permanent, impact of cesarean delivery on maternal request, 283-285
- Neuropsychological impairment, in BPD, pathways to, 230
- Neurosensory problems, in BPD, 227-228
- Neurotrophins, role in neonatal lung and airway injury, 113, 156-161
  - hyperoxia and, 157-158
- Newborn nursery, relation of cold stress and hypoglycemia to admission of preterm infants in, 24-27
- Newborn respiratory distress, and primary ciliary dyskinesia, 315, 335-338
- Newborns
  - pre-Wallerian degeneration after perinatal hypoxia-ischemia, MRI of, 113, 146-150
  - role of neurotrophins in lung and airway injury of, 113, 156-161
  - hyperoxia and, 157-158
- Nitrative stress, induced by hypercapnia, in pathogenesis of retinopathy of prematurity, 131-134
- Nitric oxide, for BPD, 215
- Nutrition, and BPD
  - pathogenesis, 176
  - prevention and management, 200-207
    - cysteine, 206
    - dexamethasone effects on growth, 201-202
    - feeding difficulties in, 201
    - glutamine, 205-206
    - growth failure and, 200-201
    - inositol, 205
    - iron, 205
    - methionine, 206
    - postdischarge nutritional management, 206
    - selenium, 205
    - trace elements, 206
    - vitamin A, 205
    - vitamin C, 205
    - vitamin E, 205
  - in VLBW infants, 202-204
- Ontogeny
  - of autonomic regulation, in late preterm infants born 34-37 weeks postmenstrual age, 73-76
    - apnea of prematurity, 74
    - apparent life-threatening events, 74
    - Collaborative Home Infant Monitoring Evaluation, 74-75
    - control of breathing, 73-74
    - maturation of sleep stage regulation, 74
    - sudden infant death syndrome, 75
  - of immune system, 69-72
    - functions of innate and adaptive systems, 70-71
    - toll-like receptors, 71-72
- Outcomes
  - neurodevelopmental. *See* Neurodevelopmental outcomes
  - pulmonary. *See* Pulmonary outcomes
  - short-term. *See* Short-term outcomes
- Oxygen therapy, for BPD, 209-211
  - in infants at 28 days vs. 36 weeks postmenstrual age, 166-167
- Parenteral nutrition
  - photoprotection of, for enhanced advancement of minimal enteral nutrition in preterm infants, 113, 139-144
  - for VLBW infants with BPD, 203
- Patent ductus arteriosus
  - and BPD pathogenesis, 175-176
  - closure in preterm newborns, intravenous ibuprofen for, 113, 114-119
  - Patent ductus arteriosus (*Continued*)
    - adverse effects and potential drug-drug interactions, 118
    - aminoglycosides interaction and renal effects, 118
    - clinical studies, 115-116
    - pharmacodynamics, 116-117
    - pharmacokinetics, metabolism and disposition, 117-118
- Patient-triggered ventilation, for BPD, 195
- Pelvic organ prolapse, development of, impact on planned vaginal delivery vs. cesarean delivery on maternal request, 272-274
- Pentoxifylline, for BPD, 215
- Periventricular leukomalacia, in late preterm infants, 81-87
- Persistent pulmonary hypertension of the newborn, caused by ibuprofen, 118
- Phosphorus, for VLBW infants with BPD, 204
- Photoprotection, of parenteral nutrition enhances advancement of minimal enteral nutrition in preterm infants, 113, 139-144
- Preeclampsia, causing preterm and late preterm births, 16-19
- Pregnancy, and anal incontinence, 261-265
- Premature rupture of membranes, and spontaneous preterm labor at late preterm gestations, management of, 98-102
  - chorioamnionitis, 99-102
  - tocolytics, 99
- Preterm infants
  - 35 and 36 weeks gestation, short-term outcomes of, 28-33
    - rehospitalization, 30-31
    - respiratory distress, 29-30
  - born by ERCS, neonatal morbidity in
    - reduced by antepartum glucocorticoids, 38
    - severe hypoxic respiratory failure, 40
    - without trial of labor, 39-40
  - intravenous ibuprofen for patent ductus arteriosus closure in, 113, 114-119
    - adverse effects and potential drug-drug interactions, 118
    - aminoglycosides interaction and renal effects, 118
    - clinical studies, 115-116
    - pharmacodynamics, 116-117
    - pharmacokinetics, metabolism and disposition, 117-118
  - late
    - born 34-37 weeks postmenstrual age ontogeny of autonomic regulation, in, 73-76
    - brain and risk of periventricular leukomalacia in, 81-87
    - drug disposition in, 48-50
    - "healthy," risk factors for neonatal morbidity and mortality among, 54-60
    - hypoglycemia and cold stress in, 24-27
    - kernicterus in, 89-97
    - place of birth and variations in management of, 44-47
    - relation of early discharge to neonatal morbidity among, 61-67
    - photoprotection of parenteral nutrition enhances advancement of minimal enteral nutrition in, 113, 139-144
- Preterm labor and birth
  - caused by preeclampsia, 16-19
  - late
    - care of women and infants in, 1, 53
    - rates of, impact of gestational age distribution among U.S. singleton births on, 8-15
    - recommended definition of, 2-5
    - stillbirths in, 20-23
  - for multiple gestations
    - elective deliveries, 109-110
    - potential indications, 107-109
    - prevention of, 106-107
  - spontaneous, and premature rupture of membranes at late preterm gestations, management of, 98-102
    - chorioamnionitis, 99-102
    - tocolytics, 99
- Pre-Wallerian degeneration, in neonate after perinatal hypoxia-ischemia, MRI of, 113, 146-150



- Primary ciliary dyskinesia  
 cilia  
   role in pulmonary defense, 336  
   structure and function, 335-336  
 diagnosis, 337  
 genetics, 337-338  
 management, 338  
 and newborn respiratory distress, 315, 335-338  
 prognosis, 338
- Psychological problems, in BPD, 230
- Pulmonary function, in BPD, 222-223
- Pulmonary outcomes, in BPD  
 airway disease, 223  
 exercise testing, 223-224  
 pathology, 219-220  
 pulmonary function, 222-223  
 radiological findings, 224  
 respiratory morbidity, 220-222
- Radiological findings, in BPD, 224
- Rehospitalization, in infants born at 35 and 36 weeks gestation, 30-31
- Reproductive health, long term effects of cesarean section on, 257-260
- Resource allocation, of cesarean delivery on maternal request, 305-308
- Respiratory distress, in infants born at 35 and 36 weeks gestation, 29-30
- Respiratory distress syndrome, and surfactant protein polymorphisms, 357-359
- Respiratory morbidity  
 in BPD, 220-222  
 after cesarean section, 296-302  
   clearance of fetal lung fluid, 299-300  
   in near-term pregnancies, 39-40  
   rescue strategies in, 301  
   role of retained fetal lung fluid, 298-299
- Respiratory syncytial virus infection, and surfactant protein polymorphisms, 358-360
- Retinoic acid, pulmonary, and interleukin-1 $\beta$  in BPD pathogenesis, 113, 121-126
- Retinopathy of prematurity, pathogenesis of, 113, 129-136  
 hypercapnia-induced nitrate stress, 131-134  
 trans-arachidonic acids and microvascular degeneration, 134-136
- Risk factors  
 of multifactor disease, surfactant polymorphism as, 350-351  
 for neonatal morbidity and mortality among "healthy," late preterm newborns, 54-60
- Selenium, for BPD, 205
- Severe hypoxic respiratory failure, ERCS-related, 40
- Sexual function, maternal, and childbirth, 253-256
- Short-term outcomes  
 of infants born at 35 and 36 weeks gestation, 28-33  
   rehospitalization, 30-31  
   respiratory distress, 29-30  
 in planned spontaneous vaginal delivery vs. cesarean section on maternal request, 247-251
- Shoulder dystocia, impact of cesarean delivery on maternal request, 277-281
- Sleep stage regulation, maturation in late preterm infants born 34-37 weeks postmenstrual age, ontogeny of, 74
- Sodium transport, in fetal lung fluid clearance, 35-36  
 role of alveolar environment, 37
- Sphincter disruption, anal incontinence after, 261-262
- Spontaneous vaginal delivery, planned, vs. cesarean section on maternal request, maternal morbidity and short-term outcomes, 247-251
- Stem cell therapy, for BPD, 215-216
- Steroids, for BPD, 212-213
- Stillbirths  
 impact of cesarean delivery on maternal request, 285-286  
 in late preterm  
   causes of, 21  
   scope of, 20-21  
   strategies for reduction of, 21-23
- Stillbirths (*Continued*)
- Sudden infant death syndrome, in late preterm infants born 34-37 weeks postmenstrual age, ontogeny of, 75
- Superoxide dismutase, for BPD, 214
- Surfactant protein-B deficiency, inherited, 315, 316-324  
 epidemiology and clinical presentation, 318  
 histopathology, 318  
 molecular basis and mechanisms, 317-318  
 and surfactant protein-C associated disease  
   epidemiology and clinical presentation, 320-321  
   evaluation, 321-323  
   histopathology, 321  
   molecular basis and mechanisms, 318-320  
   treatment, 323-324
- Surfactant protein-C associated disease  
 epidemiology and clinical presentation, 320-321  
 histopathology, 321  
 molecular basis and mechanisms, 318-320  
 and surfactant protein-B deficiency, 315, 316-324  
 epidemiology and clinical presentation, 318  
 evaluation, 321-323  
 histopathology, 318  
 molecular basis and mechanisms, 317-318  
 treatment, 323-324
- Surfactant proteins  
 and BPD pathogenesis, 172-173, 189  
 metabolism, genetically engineered mice related to  
   surfactant protein-A and D knock-outs, 346-347  
   surfactant protein-B knock-out, 344-345  
   surfactant protein-C and other promoters, 343-344, 345-346  
 polymorphism, 356-357  
   and neonatal lung disease, 315, 356-359  
   as risk factor of multifactor disease, 350-351  
 proteins as candidate genes, 351-355
- Syncytial virus infection, respiratory, and surfactant protein polymorphisms, 357-359
- Term infants, relation of early discharge to neonatal morbidity among, 61-67
- THAM-ibuprofen, for patent ductus arteriosus closure in preterm newborns, 115
- Thiazides, for BPD, 211-212
- Thyroxine, for BPD, 214
- Tocolytic agents, in spontaneous preterm labor and premature rupture of membranes at late preterm gestations, 99
- Tocopherol. *See* Vitamin E
- Toll-like receptors, in developmental regulation of immune system, 71-72
- Trace elements, for BPD, 206
- Transforming growth factor  $\beta$ , and BPD pathogenesis, 189-190
- Trauma and injury, fetal, impact of cesarean delivery on maternal request, 281-283
- Trends, of cesarean section, 235-241
- Tumor necrosis factor, and BPD pathogenesis, 190
- United States, gestational age distribution among singleton births, impact on rates of late preterm birth, 8-15
- Urinary incontinence, and cesarean delivery, 267-270  
 cross-sectional studies, 269  
 after multiple deliveries, 269  
 randomized trial, 270  
 risk of future surgery, 269-270  
 sister studies, 270
- Urokinase, and BPD pathogenesis, 190
- Vaginal delivery  
 planned  
   spontaneous, vs. cesarean section on maternal request, maternal morbidity and short-term outcomes, 247-251

Vaginal delivery (*Continued*)

- vs. cesarean delivery on maternal request, impact on development of pelvic organ prolapse, 272-274

- subsequent, effect on anal incontinence, 262-263

## Vascular maldevelopment, and BPD pathogenesis, 173-174

## Very low birth weight (VLBW) infants, with BPD, nutritional management in

- calcium, 204

- enteral intake, 203-204

- fluid restriction, 202-203

- parenteral nutrition, 203

- phosphorus, 204

Very low birth weight (VLBW) infants, with BPD, nutritional management in (*Continued*)

- vitamin D, 204

## Visual-spatial perception, in BPD, 229

## Vitamin A, for BPD, 205, 214

## Vitamin C, for BPD, 205, 214

## Vitamin D, for VLBW infants with BPD, 204

## Vitamin E, for BPD, 205, 214

VLBW infants. *See* Very low birth weight (VLBW) infants

## Volume-targeted ventilation, for BPD, 195

## Women, and infants, care in late preterm gestations, 1, 53



